


In the Claims:

Please amend claim 27 as follows.

1. (Previously Presented) A compound of formula (I):



wherein:

R¹ is alkyl;

w is 0 or 1;

R¹¹ is H or C₁₋₃alkyl;

Ring A is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

Ring B is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

a, b, c, f, g, and h are the same or different and are each independently 0 or 1;

d and j are the same or different and are independently 1 or 2;

each R² is the same or different and is independently selected from the group consisting of alkylene, alkenylene and alkynylene;

Y¹ and Y² are the same or different and are each independently selected from the group consisting of -O-, -S(O)_q- and -N(R⁵)-;

q is 0, 1 or 2;

each R³ and R⁴ are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, Het, -COR⁵, -CSR⁵, -CO₂R⁵, -COPh, -CO₂Ph, -C(O)Het, -C(O)NR⁵R⁶, -C(S)NR⁵R⁶, -C(=NR⁵)R⁶, -C(=NR⁵)NR⁵R⁶, -CR⁵=N-OR⁶, -OR⁵, -OCOR⁵, -S(O)_pR⁵, -S(O)₂OH, -S(O)_pNR⁵R⁶, -NR⁵R⁶, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁶, -NO₂, -CN, -SCN and -N₃;

each p is the same or different and is 0, 1 or 2;

m and n are the same or different and are each independently 0, 1, 2, 3, 4 or 5;

each R^5 and each R^6 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

Ph is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-CO_2R^5$, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$, $-R^2-(NR^5R^6)CO_2R^5$, Het, $-R^2$ -Het, $-CN$ and $-N_3$; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-CO_2R^5$, $-C(O)NR^5R^6$, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$, oxo, $-CN$ and $-N_3$;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1, wherein R^1 is methyl.
3. (Previously Presented) The compound according to claim 1, wherein Ring A is selected from the group consisting of aryl and 5-13 membered heteroaryl.
4. (Previously Presented) The compound according to claim 1, wherein Ring A is phenyl.
5. (Previously Presented) The compound according to claim 1, wherein Ring B is selected from the group consisting of phenyl, pyridine and pyrimidine.
6. (Previously Presented) The compound according to claim 1, wherein Ring B is phenyl.
7. (Previously Presented) The compound according to claim 1, wherein each R^2 is the same or different and is independently selected from the group consisting of alkylene and alkenylene.
8. (Previously Presented) The compound according to claim 1, wherein b is 0.
9. (Previously Presented) The compound according to claim 1, wherein b is 1 and Y^1 is selected from the group consisting of $-O-$ and $-N(R^5)-$.

10. (Previously Presented) The compound according to claim 1, wherein g is 0.
11. (Previously Presented) The compound according to claim 1, wherein g is 1 and Y² is -O-.
12. (Previously Presented) The compound according to claim 1, wherein d is 1.
13. (Previously Presented) The compound according to claim 1, wherein j is 1.
14. (Previously Presented) The compound according to claim 1, wherein each R³ is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, -COR⁵, -CO₂R⁵, -COPh, -C(O)NR⁵R⁶, -OR⁵, -S(O)_pR⁵, -S(O)_pNR⁵R⁶, -NR⁵R⁶, -NO₂, -CN and -N₃.
15. (Previously Presented) The compound according to claim 1, wherein d is 1 and R³ is selected from the group consisting of H, halo, alkyl, Ph, -COR⁵, -CO₂R⁵, -COPh, -C(O)NR⁵R⁶, -OR⁵, -NR⁵R⁶, -NO₂ and -CN.
16. (Previously Presented) The compound according to claim 1, wherein each R⁴ is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, -COR⁵, -CO₂R⁵, -C(O)NR⁵R⁶, -OR⁵, -S(O)_pR⁵, -S(O)₂OH, -S(O)_pNR⁵R⁶, -NR⁵R⁶, -NR⁵COR⁶, -NO₂ and -CN.
17. (Previously Presented) The compound according to claim 1, wherein j is 1 and R⁴ is selected from the group consisting of H, halo, alkyl, -COR⁵, -CO₂R⁵, -C(O)NR⁵R⁶, -OR⁵, -S(O)_pR⁵, -S(O)₂OH, -S(O)_pNR⁵R⁶ and -NO₂.
18. (Previously Presented) The compound according to claim 1, wherein m is 0, 1, 2 or 3.

19. (Previously Presented) The compound according to claim 1, wherein n is 1, 2, or 3.
20. (Previously Presented) The compound according to claim 1, wherein each R⁵ and each R⁶ are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl and cycloalkyl.
21. (Previously Presented) The compound according to claim 1, wherein each R⁵ and each R⁶ are the same or different and are each independently selected from the group consisting of H and alkyl.
22. (Previously Presented) A compound selected from the group consisting of:
5-Methyl-7-phenyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
5-Methyl-7-(2-nitrophenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
7-(2-Bromophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
7-(4-Fluorophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
5-Methyl-7-[3-(trifluoromethyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
2,2-Dimethyl-*N*-(2-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)propanamide;
2,2,2-Trifluoro-*N*-(2-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)acetamide;
3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzonitrile;
7-(3-Bromophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
7-(3-Bromothien-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
7-(5-Bromopyridin-3-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

Methyl 3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;
 7-(5-Bromothien-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
 7-(3-Bromophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
 7-(3-Bromophenyl)-*N*-(3-chloro-4-morpholin-4-ylphenyl)-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
 3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzamide;
 (2*E*)-3-(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)prop-2-enamide;
 5-Methyl-*N*-(4-nitrophenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
 2-{3-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}ethanol;
 4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]benzene-sulfonamide;
 7-(2-Methoxyphenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
 2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenol;
 2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl acetate;
 5-Methyl-7-[4-(trifluoromethyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;
N-Methyl-*N'*-{4-[(5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}urea;
 5-Methyl-7-phenyl-*N*-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;
 (3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)(phenyl)methanone;
 7-(1,3-Benzodioxol-5-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
 Methyl 4-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;
 5-Methyl-7-(3-phenoxyphenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
 7-(3-Aminophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(1*H*-Indol-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(5-nitro-1*H*-pyrrol-2-yl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1*H*-pyrrol-2-yl)-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1*H*-indol-3-yl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Furyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(1*H*-Indol-5-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-[(2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)thio]benzonitrile;

5-Methyl-7-(2-{[3-(trifluoromethyl)phenyl]amino}phenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-quinolin-8-yl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;

N-Methyl-*N'*-[4-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]urea;

N-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

2-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]ethanol;

4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;

N-[4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

N-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

tert-Butyl 3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzylcarbamate;

4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenol;

5-Methyl-*N*-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(5-Fluoro-2-methoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-{2-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]ethyl}acetamide;

N-[5-(2-Aminoethyl)-2-methoxyphenyl]-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(2,4-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(2,5-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

Ethyl 5-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)nicotinate;

2-{3-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}-ethanesulfonic acid;

5-Methyl-7-[3-(1*H*-pyrazol-4-ylethynyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

3'-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-3-carboxylic acid;

2-Amino-3-(3'-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo-[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-4-yl)propanoic acid;

5-Methyl-7-[2'-(trifluoromethyl)-1,1'-biphenyl-3-yl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

(2*Z*)-3-(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)-3-phenylprop-2-enamide;

7-(3-{[5-(Ethylsulfonyl)-2-methoxyphenyl]amino}phenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(3-{[4-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl]amino}phenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-{[4-(1*H*-imidazol-1-yl)phenyl]amino}phenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-{3-[(3-Chloro-4-morpholin-4-ylphenyl)amino]phenyl}-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N,N-Dimethyl-1-{3-[(3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-
f[1,2,4]triazin-7-yl}phenyl)amino]phenyl}-methanesulfonamide;

5-Methyl-7-[3-({4-[(4-methylpiperazin-1-yl)methyl]phenyl)-amino]phenyl]-*N*-(3,4,5-
trimethoxyphenyl)imidazo[5,1-f[1,2,4]triazin-2-amine;

N-Cyclopropyl-3-[(3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-
f[1,2,4]triazin-7-yl}phenyl)amino]benzenesulfonamide;

7-(5-Bromo-2-thienyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-f[1,2,4]triazin-2-
amine;

7-(3-Bromo-2-thienyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-f[1,2,4]triazin-2-
amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(tetrahydro-2H-pyran-4-yl)imidazo[5,1-
f[1,2,4]triazin-2-amine;

5-Methyl-7-[2-(methyloxy)phenyl]-*N*-[4-(methyloxy)phenyl]imidazo[5,1-f[1,2,4]triazin-
2-amine;

5-Methyl-7-[3-(methyloxy)phenyl]-*N*-[4-(methyloxy)phenyl]imidazo[5,1-f[1,2,4]triazin-
2-amine;

7-(2-Chlorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-f[1,2,4]triazin-2-
amine;

5-Methyl-7-(1-methyl-1H-indol-3-yl)-*N*-[4-(methyloxy)phenyl]imidazo[5,1-
f[1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(1-phenylethyl)imidazo[5,1-f[1,2,4]triazin-2-
amine;

5-Methyl-7-(1-methyl-1H-indol-2-yl)-*N*-[4-(methyloxy)phenyl]imidazo[5,1-
f[1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(3-thienyl)imidazo[5,1-f[1,2,4]triazin-2-amine;

7-(3-Furanyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo-[5,1-f[1,2,4]triazin-2-amine;

7-(2-Furanyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo-[5,1-f[1,2,4]triazin-2-amine;

7-(4-Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-f[1,2,4]triazin-2-
amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(2-thienyl)imidazo[5,1-f[1,2,4]triazin-2-amine;

7-Cyclopropyl-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-f[1,2,4]triazin-2-amine;

7-Cyclohexyl-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-f[1,2,4]triazin-2-amine;

7-(2-Fluorophenyl)Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-
f[1,2,4]triazin-2-amine;


5-Methyl-*N*,7-bis[4-(methyloxy)phenyl]imidazo[5,1-f[1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(phenylmethyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
7-(3-Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;
7-Cyclohexyl-5-methyl-*N*-[3,4,5-tris(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;
7-(Cyclohexylmethyl)-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;
N-[3,4-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
N-[3,5-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
N-{4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}acetamide;
5-Methyl-*N*-[4-(methylthio)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
N-(4-[[2-(Dimethylamino)ethyl]oxy]phenyl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
5-Methyl-7-phenyl-*N*-(4-[[2-(1-piperidinyl)ethyl]oxy]phenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;
N-(3-[[2-(Dimethylamino)ethyl]oxy]phenyl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
N-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
N-Cyclohexyl-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
5-Methyl-7-phenyl-*N*-(tetrahydro-2H-pyran-4-yl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;
5-Methyl-*N*-(4-[[2-(4-morpholinyl)ethyl]oxy]phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
5-Methyl-*N*-(3-[[2-(4-morpholinyl)ethyl]oxy]phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
5-Methyl-*N*-[4-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
5-Methyl-*N*,7-diphenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
5-Methyl-*N*-[3-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;
and pharmaceutically acceptable salts thereof.

23. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.


24. (Cancelled)
25. (Previously Presented) The pharmaceutical composition according to claim 23 further comprising a chemotherapeutic agent.
26. (Cancelled)
27. (Currently Amended) A method for the treatment of a neoplasm susceptible to Plk in a human ~~an animal~~ in need thereof, said method comprising administering to the human ~~animal~~ a therapeutically effective amount of a compound according to claim 1.
28. (Original) The method according to claim 27, wherein said neoplasm is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, gastric carcinoma, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma.
29. (Cancelled)
30. (Previously Presented) A method for inhibiting proliferation of a cell, said method comprising contacting the cell with an amount of a compound according to claim 1 sufficient to inhibit proliferation of the cell, wherein said compound inhibits Plk.
31. (Previously Presented) A method for inhibiting mitosis in a cell, said method comprising administering to the cell an amount of a compound according to claim 1 sufficient to inhibit mitosis in the cell, wherein said compound inhibits Plk.

32. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising reacting a compound of formula (X):




with a cyclization reagent.

33. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising reacting the compound of formula (XIII):



with a compound of formula (VI):



34. (Previously Presented) A process for preparing a compound according to claim 1 wherein:

Ring A is selected from the group consisting of cycloalkyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

each R² is the same or different and is alkylene;


each R³ and R⁴ are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, Ph, Het, -OR⁵, -S(O)ₚR⁵, -S(O)₂OH, -S(O)ₚNR⁵R⁶, -NR⁵R⁶ and -NR⁵SO₂R⁶;

each R⁵ and each R⁶ are the same or different and are each independently selected from the group consisting of H, alkyl and cycloalkyl;


Ph is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$, Het, and $-R^2$ -Het; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$ and oxo; and

said process comprising coupling a compound of formula (XVIII):



with a compound of formula (XIX):



wherein X is Cl, Br, I or triflate.

35-46. (Cancelled)